[HTML][HTML] Targeting of functional antibody-decay-accelerating factor fusion proteins to a cell surface
H Zhang, S Lu, SL Morrison, S Tomlinson - Journal of Biological Chemistry, 2001 - ASBMB
Recombinant soluble complement inhibitors hold promise for the treatment of inflammatory
disease and disease states associated with transplantation. Targeting complement inhibitors
to the site of complement activation and disease may enhance their efficacy and safety. Data
presented show that targeting of decay-accelerating factor (DAF, an inhibitor of complement
activation) to a cell surface by means of antibody fragments is feasible and that cell-targeted
DAF provides significantly enhanced protection from complement deposition and lysis …
disease and disease states associated with transplantation. Targeting complement inhibitors
to the site of complement activation and disease may enhance their efficacy and safety. Data
presented show that targeting of decay-accelerating factor (DAF, an inhibitor of complement
activation) to a cell surface by means of antibody fragments is feasible and that cell-targeted
DAF provides significantly enhanced protection from complement deposition and lysis …